IRIS
BRAVACCINI, SARA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.053
AS - Asia 1.308
EU - Europa 727
SA - Sud America 542
AF - Africa 31
OC - Oceania 2
Totale 4.663
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.003
SG - Singapore 645
BR - Brasile 483
HK - Hong Kong 391
IE - Irlanda 311
VN - Vietnam 101
IT - Italia 95
DE - Germania 88
TR - Turchia 54
FR - Francia 42
NL - Olanda 33
GB - Regno Unito 32
BD - Bangladesh 27
FI - Finlandia 26
AR - Argentina 25
CA - Canada 24
IN - India 23
MX - Messico 22
RU - Federazione Russa 22
IQ - Iraq 15
AT - Austria 14
LT - Lituania 11
UA - Ucraina 11
CO - Colombia 9
ZA - Sudafrica 9
CN - Cina 8
ES - Italia 8
TN - Tunisia 8
PL - Polonia 7
BE - Belgio 6
CZ - Repubblica Ceca 6
EC - Ecuador 6
EG - Egitto 6
JP - Giappone 6
PK - Pakistan 6
UZ - Uzbekistan 6
CL - Cile 5
ID - Indonesia 5
PY - Paraguay 5
SA - Arabia Saudita 5
SE - Svezia 5
VE - Venezuela 5
SN - Senegal 4
AZ - Azerbaigian 3
IL - Israele 3
MA - Marocco 3
AL - Albania 2
AU - Australia 2
BH - Bahrain 2
BO - Bolivia 2
KG - Kirghizistan 2
RS - Serbia 2
UY - Uruguay 2
AE - Emirati Arabi Uniti 1
BA - Bosnia-Erzegovina 1
BN - Brunei Darussalam 1
CH - Svizzera 1
DO - Repubblica Dominicana 1
GT - Guatemala 1
HN - Honduras 1
HU - Ungheria 1
IS - Islanda 1
JO - Giordania 1
KE - Kenya 1
KZ - Kazakistan 1
LB - Libano 1
MK - Macedonia 1
MY - Malesia 1
NO - Norvegia 1
TT - Trinidad e Tobago 1
Totale 4.663
Salva come PNG Salva come JPEG
Città #
Dallas 1.333
Hong Kong 389
Singapore 371
Dublin 311
Santa Clara 138
Boardman 132
The Dalles 88
São Paulo 47
Istanbul 43
Ho Chi Minh City 40
Ashburn 38
Munich 38
Assago 32
Amsterdam 23
Helsinki 23
Rio de Janeiro 22
Los Angeles 18
Frankfurt am Main 16
Hanoi 16
Brasília 11
Belo Horizonte 10
Boston 10
Chicago 10
Milan 10
Vienna 10
Düsseldorf 9
Montreal 9
New York 9
Porto Alegre 9
San Francisco 9
Brooklyn 7
Campinas 7
Haiphong 7
Ankara 6
Bexley 6
Brno 6
Brussels 6
Buenos Aires 6
Guarulhos 6
Mexico City 6
Paris 6
Salvador 6
Tokyo 6
Toronto 6
Atlanta 5
Chennai 5
Lugo 5
Manchester 5
Quito 5
Stockholm 5
Tashkent 5
Warsaw 5
Asunción 4
Bogotá 4
Contagem 4
Curitiba 4
Dakar 4
Hải Dương 4
Juiz de Fora 4
New Delhi 4
Nuremberg 4
Ottawa 4
Piracicaba 4
Ribeirão Preto 4
Riyadh 4
Rome 4
Roubaix 4
Sorocaba 4
Teresina 4
Thái Bình 4
Atibaia 3
Baku 3
Betim 3
Birmingham 3
Cairo 3
Cape Town 3
Denver 3
Dhaka 3
Erbil 3
Hortolândia 3
Houston 3
Itaquaquecetuba 3
Johannesburg 3
João Pessoa 3
Lauterbourg 3
Limeira 3
London 3
Maceió 3
Maricá 3
Milwaukee 3
Nova Iguaçu 3
Osasco 3
Palhoça 3
Passo Fundo 3
Pescara 3
Portsmouth 3
Recife 3
Santo André 3
São José dos Campos 3
São Sebastião do Paraíso 3
Totale 3.513
Salva come PNG Salva come JPEG
Nome #
The current status of biomarkers for bladder cancer: progress and challenges 138
Chronological age or biological age: What drives the choice of adjuvant treatment in elderly breast cancer patients? 79
Non-small cell lung cancer and the tumor microenvironment: making headway from targeted therapies to advanced immunotherapy. 76
Biomarkers: which ones do we really need today? 65
Expanding the Horizon of Multidisciplinarity: Incorporating Biomechanical, Metabolic, and Functional Factors Into Registry-Based Research to Predict Subsequent Risk for Total Knee Arthroplasty 64
The use of platelets as a clinical tool in oncology: opportunities and challenges 56
Re: Clinicopathological features and outcomes comparing patients with invasive ductal and lobular breast cancer 55
Knee pain and gait alterations: bridging physiology, biomechanics, and clinical practice 55
Appropriateness and Economic Analysis of Conventional Circulating Biomarkers Assessment in Early Breast Cancer: A Real-World Experience from the E.Pic.A Study 52
A functional survey of the regulatory landscape of estrogen-receptor-positive breast cancer evolution 51
Knee pain and gait alterations: bridging physiology, biomechanics, and clinical practice 50
Decoding the NRF2–NOTCH Crosstalk in Lung Cancer—An Update 48
Sacituzumab govitecan: a new opportunity in the treatment of refractory metastatic triple-negative breast cancer 48
Fluorescence In Situ Hybridization in Urine Samples (UroVysion Kit) 47
A Novel AKT1, ERBB2, ESR1, KRAS, PIK3CA, and TP53 NGS Assay: A Non-Invasive Tool to Monitor Resistance Mechanisms to Hormonal Therapy and CDK4/6 Inhibitors 46
FAP inhibitors: are we really using the best method to evaluate the residence time? 45
Androgen receptor signaling pathways as a target for breast cancer treatment 45
Are BMI and Negative Hormone Receptors Prognostic Factors in HER2+ Early-stage Breast Cancer? 45
Cell-Free DNA Variant Sequencing Using CTC-Depleted Blood for Comprehensive Liquid Biopsy Testing in Metastatic Breast Cancer 45
T-Cell Receptor Repertoire Sequencing and Its Applications: Focus on Infectious Diseases and Cancer 44
Pharmacological CDK4/6 inhibition promotes vulnerability to lysosomotropic agents in breast cancer 44
Are Androgen and Estrogen Receptors in DCIS Patients Prognostic Indicators of Relapse Independently of Treatment? 42
Urinary Biomarkers in Tumors: An Overview 41
What impacts the cost-effectiveness of PD-L1 testing in non-small cell lung cancer? 41
Tumor resident microbiota and response to therapies: An insight on tissue bacterial microbiota 40
An initiative to assess the quality of Tanzanian cervical cancer specimens for HPV and telomerase detection 40
Androgen and oestrogen receptors as potential prognostic markers for patients with ductal carcinoma insitu treated with surgery and radiotherapy 40
Androgen receptor in breast cancer: The "5W" questions 40
Combining preclinical tools and models to unravel tumor complexity: Jump into the next dimension 39
Letter to the Editor discussing: Hacker S, Lenz C, Reichert L, Ringseis R, Zentgraf K, Krüger K. Vitamin D status and its determinants in German elite athletes. Eur J Appl Physiol. 2025 Jan 4. doi: 10.1007/s00421-024–05699-6 39
Are we ready to use TMB in breast cancer clinical practice? 39
Accuracy of urine telomerase activity to detect bladder cancer in symptomatic patients 39
An H-1 NMR study of the cytarabine degradation in clinical conditions to avoid drug waste, decrease therapy costs and improve patient compliance in acute leukemia 39
Explaining the aggressiveness of breast cancer in sub-Saharan African patients 39
Nonsquamous, Non-Small-Cell Lung Cancer Patients Who Carry a Double Mutation of EGFR, EML4-ALK or KRAS: Frequency, Clinical-Pathological Characteristics, and Response to Therapy 39
Telomerase Activity Analysis In Urine Sediment for Bladder Cancer 38
Androgen Receptor Expression in Breast Cancer: What Differences Between Primary Tumor and Metastases? 38
Atezolizumab Plus Nab-paclitaxel in PD-L1-Positive TNBC-Letter 37
Evaluating the appropriateness of chemotherapy in a low-resource cancer centre in sub-Saharan Africa 37
Cell-free DNA detected by "liquid biopsy" as a potential prognostic biomarker in early breast cancer 37
Cell-free DNA detected by "liquid biopsy" as a potential prognostic biomarker in patients with different subtypes of breast cancer 37
ALK translocation detection in non-small cell lung cancer cytological samples obtained by TBNA or EBUS-TBNA 37
Are There Differences in Androgen Receptor Expression in Invasive Breast Cancer in African (Tanzanian) Population in Comparison With the Caucasian (Italian) Population? 37
Ki67 and PR in patients treated with CDK4/6 Inhibitors: A real-world experience 36
TMB in NSCLC: A Broken Dream? 36
NMR-Based Metabolomic Approach Tracks Potential Serum Biomarkers of Disease Progression in Patients with Type 2 Diabetes Mellitus 36
Predictive role of multiple gene alterations in response to cetuximab in metastatic colorectal cancer: A single center study 36
Androgen receptor in breast cancer: A wolf in sheep's clothing? A lesson from prostate cancer 36
Exploring the Relationship Between Humoral and Cellular T Cell Responses Against SARS-CoV-2 in Exposed Individuals From Emilia Romagna Region and COVID-19 Severity 36
An Italian Real-World Study Highlights the Importance of Some Clinicopathological Characteristics Useful in Identifying Metastatic Breast Cancer Patients Resistant to CDK4/6 Inhibitors and Hormone Therapy 36
Emerging Roles of Aldehyde Dehydrogenase Isoforms in Anti-cancer Therapy Resistance 36
Urinary biomarkers of nonmuscle-invasive bladder cancer: current status and future potential 36
Comprehensive genetic and epigenetic characterization of Lynch-like syndrome patients. 36
Microenvironmental determinants of cancer progression during obesity: emerging evidence and novel perspectives 36
Usefulness of immunological detection of the human telomerase reverse transcriptase 35
Significant Advancements and Evolutions in Chimeric Antigen Receptor Design 35
Safety and efficacy of anti-PD-1 inhibitors in Chinese patients with advanced lung cancer and hepatitis B virus infection: a retrospective single-center study 35
TROP2 (trophoblast cell-surface antigen 2): a drug target for breast cancer 35
Androgen receptor in advanced breast cancer: is it useful to predict the efficacy of anti-estrogen therapy? 34
ACE2 and TMPRSS2 Potential Involvement in Genetic Susceptibility to SARS-COV-2 in Cancer Patients 34
Combined Oral Fentanyl Citrate and Midazolam as Premedication for Bone Marrow Aspiration and Biopsy in Patients with Hematological Malignancies: A Randomized, Controlled and Patient-Blinded Clinical Trial 33
Exploring the promoter regions of cancer predisposition genes in patients with triple-negative breast cancer reveals the presence of rare germline variants 33
New Biomarkers to Predict the Evolution of In Situ Breast Cancers 33
Pro-apoptotic effect of a nitric oxide-donating NSAID, NCX 4040, on bladder carcinoma cells 32
Urine cell-free DNA integrity as a marker for early bladder cancer diagnosis: preliminary data 32
Relevance of urine telomerase in the diagnosis of bladder cancer 32
Are fine-needle aspiration biopsy-derived cell blocks a useful surrogate for tissue samples in breast cancer? 32
Is Ki67 still a powerful ally in predicting the clinical benefit of anthracyclines for the adjuvant treatment of early breast cancer? 31
The current status of biomarkers for bladder cancer: progress and challenges 31
Impressive clinical response to anti-PD-1 therapy in epithelioid mesothelioma with high clonal PD-L1 expression and EML4-ALK rearrangement 31
Programmed death ligand 1 expression in early stage, resectable non-small cell lung cancer 31
Why the complications of COVID-19 patients differ in elderly and young cancer patients 31
Expanding Roles of De Novo Lipogenesis in Breast Cancer 30
What Influences the Choice of Ibrutinib-Rituximab vs Classic Chemoimmunotherapy for Chronic Lymphocytic Leukemia? 30
What to look for in cell-free DNA from breast cancer patients 30
In-111-Pentetreotide (OctreoScan) scintigraphy in the staging of small-cell lung cancer: its accuracy and prognostic significance 30
Analysis of Genetic Alterations in Tunisian Patients with Lung Adenocarcinoma 30
Frequency of actionable alterations in epidermal growth factor receptor (EGFR) wild type non-small cell lung cancer: experience of the Wide Catchment Area of Romagna (AVR) 29
Human papillomavirus E6 alters Toll-like receptor 9 transcripts and chemotherapy responses in breast cancer cells in vitro 29
Epithelial-to-mesenchymal transition and EGFR status in NSCLC: the role of vimentin expression 29
Re: "Evolution of low HER2 expression between early and advanced-stage breast cancer" 29
Follicular Lymphoma Microenvironment Traits Associated with Event-Free Survival 29
Setting Up a Medical Oncology Educational Program in Sub-Saharan Africa 28
Combined analysis of miR-200 family and its significance for breast cancer 28
Spotlight on PSMA as a new theranostic biomarker for bladder cancer 28
International consensus on severe lung cancer-the first edition 28
Unraveling the protein kinase C/NDRG1 signaling network in breast cancer. 28
International expert consensus on diagnosis and treatment of lung cancer complicated by chronic obstructive pulmonary disease. 28
Spotlight on Ki67 as a prognostic marker in early breast cancer: all that glitters may not be gold 28
Erratum to: Benefit from anthracyclines in relation to biological profiles in early breast cancer 28
Palbociclib (PD 0332991): targeting the cell cycle machinery in breast cancer 27
Urine telomerase: An important marker in the diagnosis of bladder cancer 27
The current role of telomerase in the diagnosis of bladder cancer 27
Role of Telomerase in Cervical Lesions as Prognostic Marker: A Comparison Between Immunohistochemistry and Fluorescence In Situ Hybridization 27
Frequency of Actionable Alterations in EGFR wt NSCLC: Experience of the Wide Catchment Area of Romagna (AVR) 27
Triple negative breast cancer in a poor resource setting in North-Western Tanzania: a preliminary study of 52 patients 27
No more disparities among regions in Italy: recent approval of genomic test reimbursability for early breast cancer patients in the country 27
Molecular determinations of EGFR and EML4-ALK on a single slide of NSCLC tissue 27
CAR T cells targeting options in the fight against multiple myeloma 27
Urine telomerase activity for the detection of bladder cancer in females 27
Totale 3.828
Salva come PNG Salva come JPEG
Categoria #
all - tutte 29.713
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 29.713
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2023/2024187 0 0 0 0 0 0 0 0 0 0 0 187
2024/20252.496 264 71 193 57 234 318 149 135 304 299 283 189
2025/20262.238 313 965 545 415 0 0 0 0 0 0 0 0
Totale 4.921